Guardant Health (GH) – Investment Analysts’ Recent Ratings Changes

Guardant Health (NASDAQ: GH) recently received a number of ratings updates from brokerages and research firms:

• 8/4/2026 – Guardant Health had its price target raised by Stephens from $170.00 to $195.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Guardant Health had its price target raised by Piper Sandler from $135.00 to $193.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Guardant Health had its price target raised by Morgan Stanley from $175.00 to $185.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Royal Bank Of Canada from $185.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Guardant Health was given a new $210.00 price target by Royal Bank Of Canada.
• 7/31/2026 – Guardant Health had its price target raised by TD Cowen from $200.00 to $210.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Stifel Nicolaus from $130.00 to $180.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $210.00 price target on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Mizuho from $175.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by BTIG Research from $190.00 to $195.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Barclays PLC from $150.00 to $200.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by JPMorgan Chase & Co. from $185.00 to $195.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Guardant Health had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Guardant Health had its price target raised by Guggenheim from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Guardant Health had its price target raised by Canaccord Genuity Group Inc. from $135.00 to $205.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Guardant Health had its price target raised by Morgan Stanley from $130.00 to $175.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Guardant Health had its price target raised by Citigroup Inc. from $150.00 to $215.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Guardant Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $200.00 price target on the stock.
• 7/6/2026 – Guardant Health had its price target raised by Bank of America Corporation from $135.00 to $190.00. They now have a “buy” rating on the stock.
• 7/2/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 7/2/2026 – Guardant Health had its price target raised by Sanford C. Bernstein from $175.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/1/2026 – Guardant Health had its price target raised by BTIG Research from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Guardant Health had its price target raised by Guggenheim from $135.00 to $160.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Guardant Health is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $175.00 price target on the stock.
• 6/25/2026 – Guardant Health was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Guardant Health was given a new $150.00 price target by UBS Group AG.
• 6/24/2026 – Guardant Health had its price target raised by Barclays PLC from $120.00 to $150.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling

In other news, insider Terilyn J. Monroe sold 46,300 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. The trade was a 66.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Chris Freeman sold 63,605 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the completion of the transaction, the insider owned 65,374 shares of the company’s stock, valued at $11,086,122.92. This trade represents a 49.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 546,224 shares of company stock valued at $80,435,493 over the last three months. Company insiders own 5.60% of the company’s stock.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.